From: CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer
Parameters | HR | 95% CI | P value |
---|---|---|---|
Age (years) (≥ 65 vs. <65) | 1.332 | 1.013–1.751 | 0.040* |
Sex (male vs. female) | 1.063 | 0.778–1.452 | 0.703 |
Tumour Location |  |  | < 0.001* |
Proximal gastric cancer | 1.373 | 1.026–1.837 | 0.033* |
Distal gastric cancer | 1 | Â | Â |
Total stomach | 3.379 | 1.902–6.004 | < 0.001* |
Borrmann type (III/IV vs. I/II) | 1.340 | 0.960–1.870 | 0.080 |
Lauren type | Â | Â | 0.063 |
Intestinal | 1 | Â | Â |
Diffuse | 1.247 | 0.920–1.691 | 0.155 |
Mixed | 1.570 | 1.052–2.344 | 0.027* |
Tumour size (cm) (≥ 5 vs. <5) | 1.708 | 1.273–2.293 | < 0.001* |
pT stage (T3/4 vs. T1/2) | 2.966 | 1.520–5.788 | 0.001* |
pN stage (N2/3 vs. N0/1) | 3.038 | 2.101–4.392 | < 0.001* |
pTNM stage (III/IV vs. I/II) | 2.299 | 1.464–3.612 | < 0.001* |
HER2 | 1.106 | 0.704–1.737 | 0.661 |
PD-L1 | 0.991 | 0.720–1.362 | 0.953 |
CLDN18.2 expression | 1.366 | 1.035–1.803 | 0.028* |